Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies aims to raise up to $230 million in an initial public offering, according to documents filed yesterday with the US Securities and Exchange Commission.

The Seattle, Washington-based immunosequencing firm did not disclose an expected share price range but said it plans to trade under the symbol ADPT on the Nasdaq. Goldman Sachs, JP Morgan, Bank of America, Merrill Lynch, Cowen, William Blair, Guggenheim Securities, and BTIG will serve as underwriters of the IPO.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.